Please assess the completion status of the following clinical trial:

Trial Title: Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subject must have a diagnosis of psoriatic arthritis (PsA) by the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria.~* Subject has ≥ 3 tender and ≥ 3 swollen joints at screening and at baseline.~* Subject has an active psoriatic skin lesion~* Subject is naïve to etanercept and any other biologic for the treatment for PsA or psoriasis.~* Subject has no prior use of methotrexate for PsA.~* Subject has no history of tuberculosis~* Subject has a negative test for tuberculosis, hepatitis B and C.~Exclusion Criteria:~* Subject has known history of alcoholic hepatitis, nonalcoholic steatohepatitis or immunodeficiency syndromes, including human immunodeficiency virus (HIV) infection.~* Subject has any active infection (including chronic or localized infections) for which anti-infectives were indicated within 4 weeks prior to the first dose of investigational product.~* Subject has a serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to the first dose of investigational product.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methotrexate Monotherapy (Type: ACTIVE_COMPARATOR): Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.
- Etanercept Monotherapy (Type: EXPERIMENTAL): Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.
- Methotrexate + Etanercept (Type: EXPERIMENTAL): Participants received etanercept 50 mg a week by subcutaneous injection plus oral methotrexate 20 mg weekly for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).